JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270 monoclonal antibody (JJP-1008) aimed at selective inhibition of its regulatory interactions. CD270, also known as HVEM, is a checkpoint inhibitor involved in the progression of various cancers, including melanoma, pancreatic and colon cancers.
December 02, 2024
Warsaw, Poland – JJP Biologics reached a new milestone by initiation of CMC (Chemistry, Manufacturing, and Controls) work phase for its first-in-class CD270 checkpoint inhibitor program, JJP-1008. CD270 is one of the crucial immune checkpoints involved in various types of cancer, including melanoma. By initiating CMC, JJP Biologics starts its journey to produce active substance and drug products for future clinical trials with JJP-1008.
JJP-1008
JJP-1008 is a first-in-class IgG4-κ CD270 immune checkpoint inhibitor monoclonal antibody being developed for personalized cancer treatment. High CD270 expression on cancer cells suppresses the immune response, leading to poor prognosis. JJP-1008 binds to an epitope of CD270 which enables strong activation of the immune response to fight the tumor. In metastatic melanoma, CD270 expression is mutually exclusive with PD-L1 and is linked to resistance against PD1-PD-L1 inhibitors. To address this, JJP Biologics is developing a companion diagnostic to identify patients with elevated CD270 tumor expression, who are most likely to benefit from JJP-1008. Beyond metastatic melanoma, JJP Biologics discovered an identical tumor microenvironment fingerprint in a range of solid tumors and leukemia, which increases the potential therapeutic value of JJP-1008.
The JJP-1008 project is co-financed from the state budget by the Polish Medical Research Agency (No: 2022/ABM/05/00015 ).
JJP BIOLOGICS
JJP Biologics is a privately funded, clinical stage biotechnology company that specializes in the development of therapeutic monoclonal antibodies accompanied by companion diagnostics for personalized treatments. JJP Biologics pursues the development of its own product candidates as well as projects executed in cooperation with scientific partners. By targeting specific immune pathways, the company’s products have broad applications in autoimmune diseases and cancer. JJP Biologics’ current product pipeline includes the most advanced JJP-1212, a first-in-class anti-CD89 antagonizing monoclonal antibody for the treatment of various autoimmune and fibrotic diseases, and JJP-1008, a first-in-class CD270 immune checkpoint inhibiting monoclonal antibody, for the treatment of various oncological indications.
For further information, please contact: info@jjp.bio
Follow us on LinkedIn: Be a smart goose https://lnkd.in/eZV3ZbS9